sb 202190 has been researched along with Thrombosis in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lidington, EA | 1 |
| Haskard, DO | 1 |
| Mason, JC | 1 |
1 other study available for sb 202190 and Thrombosis
| Article | Year |
|---|---|
Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
Topics: CD55 Antigens; Cells, Cultured; Complement Activation; Complement System Proteins; Endothelial Growt | 2000 |